Autopsy report · NCT04402008

Study of Poziotinib in Japanese Patients With NSCLC

“Business decision, not related to safety.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 2 years 8 months before it stopped.
• 42 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Spectrum Pharmaceuticals, Inc

Sponsor type

Industry

Conditions

NSCLC

Interventions

Poziotinib Once Daily Dosing; Poziotinib Twice Daily Dosing; Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1

Participants

42

Sites

3

Countries

Japan

Trials that died the same way

• A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
  “business decision, not safety reasons.” (90% match in meaning)
• Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes
  “Business Decision; No Safety Or Efficacy Concerns. (See below)” (82% match in meaning)
• Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury
  “Based on a business decision unrelated to any safety concerns.” (81% match in meaning)
• A Single and Multiple Ascending Dose Study of JNJ-64457744
  “Strategic business decision, not due to safety concerns” (81% match in meaning)
• Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
  “Company decision not related to any safety concerns.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.